Wealth Enhancement Advisory Services
KROS icon

Wealth Enhancement Advisory Services’s Keros Therapeutics KROS Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$174K Sell
14,964
-2,877
-16% -$31.5K ﹤0.01% 3797
2026
Q2 		$211K Buy
+17,841
New +$199K ﹤0.01% 3543

Other funds holding KROS

GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Wealth Enhancement Advisory Services's KROS Position: Q3 2026 in Review

Wealth Enhancement Advisory Services reduced its Keros Therapeutics (KROS) stake by 16% in Q3 2026, selling an estimated $31.5K and leaving 14,964 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #3797.

Wealth Enhancement Advisory Services first reported a position in KROS in Q2 2026 and has held it in 2 quarters since. The position peaked at $211K in Q2 2026. 6 funds tracked by Wall St. Rank hold KROS as of Q3 2026.

  • Wealth Enhancement Advisory Services held 14,964 shares of Keros Therapeutics worth $174K as of Q3 2026.
  • Wealth Enhancement Advisory Services sold 2,877 Keros Therapeutics shares in Q3 2026, an estimated $31.5K.
  • Keros Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #3797 holding.
  • Wealth Enhancement Advisory Services first reported a position in Keros Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Wealth Enhancement Advisory Services's Keros Therapeutics position peaked at $211K in Q2 2026.
  • 6 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.